You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
內地新冠疫苗第二劑次加強免疫接種實施方案出爐 疫苗股揚升
國務院聯防聯控機制印發新冠疫苗第二劑次加強免疫接種實施方案,現階段,可在第一劑次加強免疫接種基礎上,在感染高風險人群、60歲以上老年人群、具有較嚴重基礎性疾病人群和免疫力低下人群中開展第二劑次加強免疫接種。 根據疫苗研發工作進展,所有批准附條件上市或緊急使用的疫苗均可用於第二劑次加強免疫。優先考慮序貫加強免疫接種,或採用含奧密克戎毒株或對奧密克戎毒株具有良好交叉免疫的疫苗進行第二劑次加強免疫接種 根據國內外真實世界研究和臨床試驗數據,結合內地疫苗接種實際,第二劑次加強免疫與第一劑次加強免疫時間間隔為六個月以上。 在港上市的疫苗股揚升,康希諾生物(06185.HK)現報90.6元,升6.6%,成交905.54萬股,涉資8.01億元。瑞科生物-B(02179.HK)現報25.55元,升13.8%。諾誠健華-B(09969.HK)現報14.44元,升8.6%。和鉑醫藥-B(02142.HK)現報2.03元,升5.7%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account